Entera Bio Announces Open Market Purchases of Company Stock by Board Members

Core Viewpoint - Entera Bio Ltd. has announced that several members of its Board of Directors, including the Chairman, have made open market purchases of the Company's ordinary shares, indicating confidence in the Company's future prospects [1][2]. Group 1: Board Purchases - The purchases were made by Geno J. Germano (Chairman), Steven D. Rubin, Haya Taitel, and Sean Ellis, all Directors of the Company [2]. - These transactions were conducted at prevailing market prices and are reported in filings with the U.S. Securities and Exchange Commission [2]. Group 2: Company Overview - Entera Bio is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs [4]. - The Company utilizes a proprietary technology platform (N-Tab®) and has a pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2 [4]. - The most advanced product candidate, EB613, is being developed as the first oral osteoanabolic treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis [4]. - A Phase 2 study of EB613 met primary and secondary endpoints, demonstrating its potential effectiveness [4]. - Entera is also developing the first oral oxyntomodulin for obesity and metabolic syndromes, and the first oral GLP-2 peptide for rare malabsorption conditions in collaboration with OPKO Health [4].